Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients

Halahleh, Khalid; Sawajneh, Suhaib; Saleh, Yacob; Shahin, Omar; Abufara, Alaa; Ma'koseh, Mohamad; Abdel-Razeq, Rashid; Barakat, Fareed; Abdelkhaleq, Hadeel; Al-Hassan, Nadira; Atiyyat, Reem; Al-Faker, Noor; Omari, Zaid; Ghatasheh, Hamza; Jaradat, Imad; Muradi, Isa; Iyad, Sultan; Bazarbachi, Ali

doi:10.1016/j.clml.2022.02.009

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Questions have been raised concerning the ideal time frame for thoroughly evaluating the efficacy and safety of pembrolizumab because Chen et al indicate positive trends over a two-year follow-up while Armand et al retain consistent results over a lengthier four-year follow-up [11,14]. In conclusion, current research shows the promise of pembrolizumab in the treatment of cHL but also points out differences in the reporting of adverse events and the length of follow-up, requiring more study and customized treatment choices [26][27][28][29].…”

Section: Agreement and Disagreement With Contemporary Researchmentioning

confidence: 74%

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Hossain,

Kharel,

Akter

et al. 2023

Cureus

View full text Add to dashboard Cite

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherapy for recurrent and relapsed cHL. We found eight appropriate articles through systematic search and conducted in-depth analysis to find insights into the effectiveness and safety profiles of pembrolizumab by analyzing clinical trial data in patients with recurrent and relapsed cHL. Analysis of the studies shows that response rates, progression-free survival, and patient-reported quality of life have all significantly improved. However, immune-related consequences are among the adverse outcomes. The necessity for continued study is highlighted by the variation in reported adverse events and follow-up times. Clinicians, researchers, and other healthcare professionals can use this study as a resource to provide knowledgeable and individualized patient care in cHL.

show abstract

Section: Agreement and Disagreement With Contemporary Researchmentioning

confidence: 74%

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Hossain,

Kharel,

Akter

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Fifteen patients with R/R HL were included in the international study, with 60% achieving objective response with pembrolizumab monotherapy [ 39 ]. Another study which included pediatric patients showed improved survival outcomes in those receiving pembrolizumab prior to HSCT [ 86 ].…”

Section: Checkpoint Inhibitor Use In Pediatric Oncologymentioning

confidence: 99%

Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?

Ciurej,

Lewis,

Gupte

et al. 2023

Vaccines

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by “turning off the brakes” of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy. Through our review, we propose the consideration of ICI as standard therapy in lymphoma and various solid tumor types, especially in relapsed or refractory (R/R) disease. However, further studies are needed to demonstrate ICI effectiveness in pediatric leukemia.

show abstract

“…In addition, autologous and allogeneic hematopoietic cell transplantation have been occupying a relevant place in treating R/R HL since several decades. Last but not the least, other investigational cellular therapies have raised increased interest as potentially efficacious anti-CD30 targeting model [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Leroyer

Ziegler

Moulin

et al. 2022

JCM

View full text Add to dashboard Cite

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

show abstract

Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients

Cited by 5 publications

References 21 publications

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Contact Info

Product

Resources

About